Payment overview · 2025
General Payments
$1,276.64
66 reported records · 19 companies
Healthcare provider profile · identity verified
Mohammad Omer Iqbal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINSTON, NC · NPI 1043226574
Verified facts
What the public records show
CMS Open Payments records show Mohammad Omer Iqbal, MD received $1,276.64 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $258.52 | 20.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $215.84 | 16.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.34 | 12.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.56 | 8.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.91 | 6.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.83 | 4.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.35 | 3.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.58 | 3.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.38 | 3.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.40 | 3.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.77 | 2.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.27 | 2.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.25 | 2.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.31 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.15 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.96 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.70 | 1.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.38 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.14 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,276.64 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $242.72 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $215.84 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $185.95 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $170.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $149.11 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.99 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.99 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $64.87 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.54 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.40 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 368 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 233 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 202 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 68 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 227 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 243 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 170 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
227 | 59 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
233 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
170 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
243 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
368 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1482 | 350 |
| Amlodipine Besylate | Amlodipine Besylate | 1304 | 321 |
| Omeprazole | Omeprazole | 949 | 206 |
| Gabapentin | Gabapentin | 937 | 209 |
| Potassium Chloride | Potassium Chloride | 813 | 183 |
| Metformin Hcl | Metformin Hcl | 730 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 711 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 632 | 157 |
| Pantoprazole Sodium | Pantoprazole Sodium | 622 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 107 |
| Furosemide | Furosemide | 553 | 149 |
| Lisinopril | Lisinopril | 545 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 540 | 123 |
| Allopurinol | Allopurinol | 483 | 104 |
| Losartan Potassium | Losartan Potassium | 452 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 430 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 428 | 118 |
| Metoprolol Tartrate | Metoprolol Tartrate | 411 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 392 | 84 |
| Eliquis | Apixaban | 368 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 364 | 85 |
| Finasteride | Finasteride | 331 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 308 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 289 | 94 |
| Torsemide | Torsemide | 282 | 67 |
| Sertraline Hcl | Sertraline Hcl | 269 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 266 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 253 | 67 |
| Carvedilol | Carvedilol | 246 | 63 |
| Ozempic | Semaglutide | 243 | 43 |
| Farxiga | Dapagliflozin Propanediol | 233 | 49 |
| Linzess | Linaclotide | 227 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 226 | 56 |
| Glimepiride | Glimepiride | 224 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 221 | 55 |
| Mirtazapine | Mirtazapine | 214 | 51 |
| Montelukast Sodium | Montelukast Sodium | 210 | 40 |
| Simvastatin | Simvastatin | 207 | 49 |
| Jardiance | Empagliflozin | 202 | 40 |
| Glipizide | Glipizide | 199 | 40 |
| Meloxicam | Meloxicam | 196 | 60 |
| Donepezil Hcl | Donepezil Hcl | 193 | 37 |
| Trazodone Hcl | Trazodone Hcl | 192 | 45 |
| Alendronate Sodium | Alendronate Sodium | 180 | 45 |
| Enalapril Maleate | Enalapril Maleate | 180 | 38 |
| Prednisone | Prednisone | 180 | 133 |
| Atenolol | Atenolol | 175 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 175 | 35 |
| Ezetimibe | Ezetimibe | 172 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 170 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 33 |
| Famotidine | Famotidine | 166 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 161 | 40 |
| Clonidine Hcl | Clonidine Hcl | 158 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 149 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 146 | 28 |
| Colchicine | Colchicine | 136 | 43 |
| Spironolactone | Spironolactone | 132 | 35 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 126 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 123 | 72 |
| Naproxen | Naproxen | 118 | 56 |
| Azithromycin | Azithromycin | 117 | 100 |
| Pregabalin | Pregabalin | 114 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 78 |
| Propranolol Hcl | Propranolol Hcl | 103 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 22 |
| Celecoxib | Celecoxib | 97 | 22 |
| Warfarin Sodium | Warfarin Sodium | 96 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 61 |
| Nifedipine Er | Nifedipine | 92 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Glipizide Er | Glipizide | 87 | 24 |
| Levetiracetam | Levetiracetam | 87 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 86 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 84 | 32 |
| Azelastine Hcl | Azelastine Hcl | 83 | 35 |
| Trulicity | Dulaglutide | 83 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 55 |
| Nystatin | Nystatin | 79 | 36 |
| Rybelsus | Semaglutide | 78 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 18 |
| Januvia | Sitagliptin Phosphate | 73 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 14 |
| Kerendia | Finerenone | 68 | 11 |
| Cefuroxime | Cefuroxime Axetil | 66 | 50 |
| Tramadol Hcl | Tramadol Hcl | 66 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 17 |
| Mounjaro | Tirzepatide | 64 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 55 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Alprazolam | Alprazolam | 62 | 16 |
| Methylprednisolone | Methylprednisolone | 60 | 56 |
| Repatha Sureclick | Evolocumab | 60 | 11 |
| Valsartan | Valsartan | 60 | 16 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Lovastatin | Lovastatin | 59 | 15 |
| Meclizine Hcl | Meclizine Hcl | 59 | 23 |
| Metolazone | Metolazone | 59 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Digoxin | Digoxin | 55 | 11 |
| Ibuprofen | Ibuprofen | 53 | 22 |
| Methotrexate | Methotrexate Sodium | 53 | suppressed |
| Lorazepam | Lorazepam | 52 | suppressed |
| Topiramate | Topiramate | 52 | 14 |
| Verapamil Er | Verapamil Hcl | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 51 | 16 |
| Metformin Hcl Er | Metformin Hcl | 51 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 42 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 48 | suppressed |
| Gemfibrozil | Gemfibrozil | 48 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 14 |
| Cephalexin | Cephalexin | 46 | 34 |
| Etodolac | Etodolac | 46 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 15 |
| Levemir Flexpen | Insulin Detemir | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Febuxostat | Febuxostat | 43 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Ketoconazole | Ketoconazole | 41 | 15 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 41 | 31 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Klor-Con M20 | Potassium Chloride | 38 | 20 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 14 |
| Ammonium Lactate | Ammonium Lactate | 33 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Ciclopirox | Ciclopirox | 31 | 18 |
| Cilostazol | Cilostazol | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 13 |
| Diazepam | Diazepam | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 11 |
| Trulance | Plecanatide | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 13 |
| Lactulose | Lactulose | 27 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Ramipril | Ramipril | 25 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 20 |
| Prolia | Denosumab | 21 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Mitigare | Colchicine | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Fluconazole | Fluconazole | 18 | 13 |
| Loperamide | Loperamide Hcl | 18 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,276.64 · 66 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error